Clinical Development
To date, briquilimab has been evaluated in more than 130 healthy volunteers and patients. This humanized antibody is being studied in Jasper-sponsored clinical trials in multiple diseases.
- SCID Transplant (ongoing): Phase 1/2 dose-escalation and expansion trial is evaluating briquilimab as a sole conditioning agent to achieve donor stem cell engraftment in patients undergoing hematopoietic stem cell transplantation for SCID, which is potentially curable only by this type of treatment. (NCT02963064)
- AML/MDS transplant (ongoing): A Phase 1 trial is evaluating Briquilimab in combination with another low-intensity conditioning regimen in patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing hematopoietic stem cell transplantation. (NCT04429191)
- Low to Intermediate Risk MDS (upcoming): A clinical study to evaluate briquilimab as a chronic therapeutic for transfusion dependent low to intermediate risk MDS patients.
- Chronic Urticaria (upcoming): A clinical study to evaluate briquilimab as a chronic therapeutic for patients with Chronic Urticaria.